Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vistry H1 profits in line with expectations

(Sharecast News) - Housebuilder Vistry said on Thursday that H1 profits were in line with expectations at roughly £125.0m, underpinning the group's confidence in its FY outlook. Vistry said H1 group revenues were expected to be approximately £200.0m lower at £1.8bn as it delivered roughly 6,800 completions in H1, down from 7,792 a year earlier, with roughly 73% of which being partner funded, while the remaining 27% were open market. Sales rates averaged 1.022, down from 1.21 in H124, with average selling prices "remaining firm".

The FTSE 250-listed company noted that cash generation improved in H1, with Vistry's net debt sitting at roughly £295.0m at the end of June, down £27.0m on the prior year level, despite a £92.0m higher opening net debt position on 31 December 2024.

Vistry also said it remains on track to deliver a year-on-year increase in profits in FY25, supported by a forward order book of £4.3bn, 79% of which was forward sold, and a "strong" pipeline of development opportunities.

Chief executive Greg Fitzgerald said: "I am pleased to report that the group has delivered first half profits in line with expectations, which underpin the board's confidence in its full-year outlook.

"Working with our partners, we have good momentum and a strong deal pipeline, which support our second half delivery and medium-term targets."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.